AI radiology company Aidoc revealed on Tuesday that the US Food and Drug Administration (FDA) has cleared the world's first AI solution for the treatment of cervical spine (C-spine) fractures.
This latest US FDA 510(k) clearance is reportedly the company's third in nine months and follows the recent US FDA clearance of the pulmonary embolism solution.
The company added that the AI-powered triage automatically prioritizes critical cases, ensuring that they are diagnosed by a radiologist in the most timely manner.
According to the company, the recent studies show that 54% of radiologists feel "burnt out" due to long work hours and on-the-job stress. AI-driven workflow triage is especially beneficial for empowering the radiologist by maintaining quality across the workflow, increasing confidence in treating critical patients on time, while making radiologists' work a lot more rewarding and less tedious.
In conjunction, the company's CEO Elad Walach will present its suite of AI-based workflow solutions at booth 513on an Ask Industry panel on the topic of 'AI in Practice – Where Are We Now?' at the SIIM 2019 annual meeting.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML